Literature DB >> 19757195

Is predisposition for nephroblastoma linked to polymorphisms of the WTX gene?

Barbara Guertl1, Ivo Leuschner, Christian Guelly, Birgit Ebner, Cornelia Kronberger, Gerald Hoefler.   

Abstract

Inactivation of Wilms tumor X (WTX) gene has been linked to the pathogenesis of a varying percentage of nephroblastomas. In contrast, germline mutations of WTX were identified to cause bone dysplasia, but not to induce the development of nephroblastomas. In our study we investigated whether tumor promotion of nephroblastoma by inactivation of WTX gene is linked to certain single nucleotide polymorphisms (SNPs). Therefore 8 SNPs-distributed over the whole length of the WTX gene-were investigated by high resolution melting curve analysis (HRMA) and sequencing of genomic DNA from nephroblastoma patients (NB) and controls. No difference was detected in the 8 SNPs investigated, which were distributed over the whole length of the gene. Additionally, sequence analysis of the coding part of the WTX gene of the tumor samples revealed no chromosomal aberration. Our study indicates, that inactivation of WTX appears to be a late event in tumorigenesis of nephroblastoma in a subgroup of nephroblastomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19757195     DOI: 10.1007/s12253-009-9205-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  6 in total

1.  An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.

Authors:  Miguel N Rivera; Woo Jae Kim; Julie Wells; David R Driscoll; Brian W Brannigan; Moonjoo Han; James C Kim; Andrew P Feinberg; William L Gerald; Sara O Vargas; Lynda Chin; A John Iafrate; Daphne W Bell; Daniel A Haber
Journal:  Science       Date:  2007-01-04       Impact factor: 47.728

Review 2.  Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour.

Authors:  R H Scott; C A Stiller; L Walker; N Rahman
Journal:  J Med Genet       Date:  2006-05-11       Impact factor: 6.318

3.  Genetic clonality is a feature unifying nephroblastomas regardless of the variety of morphological subtypes.

Authors:  Barbara Guertl; Ivo Leuschner; Dieter Harms; Gerald Hoefler
Journal:  Virchows Arch       Date:  2006-05-20       Impact factor: 4.064

4.  Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis.

Authors:  Zandra A Jenkins; Margriet van Kogelenberg; Tim Morgan; Aaron Jeffs; Ryuji Fukuzawa; Esther Pearl; Christina Thaller; Anne V Hing; Mary E Porteous; Sixto Garcia-Miñaur; Axel Bohring; Didier Lacombe; Fiona Stewart; Torunn Fiskerstrand; Laurence Bindoff; Siren Berland; Lesley C Adès; Michel Tchan; Albert David; Louise C Wilson; Raoul C M Hennekam; Dian Donnai; Sahar Mansour; Valérie Cormier-Daire; Stephen P Robertson
Journal:  Nat Genet       Date:  2008-12-14       Impact factor: 38.330

5.  Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors.

Authors:  D Perotti; B Gamba; M Sardella; F Spreafico; M Terenziani; P Collini; A Pession; M Nantron; F Fossati-Bellani; P Radice
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

6.  The GNAS1 T393C polymorphism predicts survival in patients with advanced squamous cell carcinoma of the larynx.

Authors:  Goetz F Lehnerdt; Peter Franz; Sebastian Winterhoff; Agnes Bankfalvi; Sara Grehl; Stephan Lang; Kurt W Schmid; Winfried Siffert; Klaus Jahnke; Ulrich H Frey
Journal:  Laryngoscope       Date:  2008-12       Impact factor: 3.325

  6 in total
  2 in total

Review 1.  The yin and yang of kidney development and Wilms' tumors.

Authors:  Peter Hohenstein; Kathy Pritchard-Jones; Jocelyn Charlton
Journal:  Genes Dev       Date:  2015-03-01       Impact factor: 11.361

2.  Mir-20a-5p induced WTX deficiency promotes gastric cancer progressions through regulating PI3K/AKT signaling pathway.

Authors:  Jian Li; Danli Ye; Peng Shen; Xiaorong Liu; Peirong Zhou; Guifang Zhu; Yangwei Xu; Yun Fu; Xuanqi Li; Jingbo Sun; Jia Xu; Qingling Zhang
Journal:  J Exp Clin Cancer Res       Date:  2020-10-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.